Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

Business Wire November 9, 2017

Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare Conference

Business Wire November 8, 2017

Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Business Wire November 8, 2017

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS

Business Wire November 7, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS

PR Newswire November 7, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Manitex International, Inc. (MNTX)

PR Newswire November 7, 2017

Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare Conference

Business Wire October 31, 2017

Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis

Business Wire October 27, 2017

Alkermes to Initiate New Clinical Study Evaluating ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

Business Wire October 26, 2017

Alkermes Unveils Investigational Product Designed for Initiation Onto ARISTADA® for Treatment of Schizophrenia

Business Wire October 26, 2017

Alkermes plc Reports Third Quarter 2017 Financial Results

Business Wire October 26, 2017

Alkermes Plc to Host Earnings Call

Accesswire October 26, 2017

Alkermes to Host Conference Call to Discuss Third Quarter 2017 Financial Results

Business Wire October 19, 2017

New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry

Business Wire October 18, 2017

Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting

Business Wire October 16, 2017

Stock Performance Review on Drug Delivery Industry -- Adamis Pharma, Alkermes, PetMed Express, and Valeant Pharma

PR Newswire October 5, 2017

Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis

Business Wire September 28, 2017

Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®

Business Wire September 18, 2017

Watch These 8 Huge Call Purchases In Friday Trade

Benzinga.com  September 8, 2017

Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

Business Wire September 6, 2017